You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 4
  • 388 Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients

Article info

Article menu

Download PDFPDF

Palliative care
388 Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients
Free

Authors

Citation

Peen U, Graybill W, González-Martin A, et al
388 Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients
International Journal of Gynecologic Cancer 2020;30:A90-A91.

Publication history

  • First published December 4, 2020.
Online issue publication 
February 04, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.